title: Patients with bullous pemphigoid and linear IgA disease show a dual IgA and IgG autoimmune response to BP180.
abstract: Bullous pemphigoid (BP) and linear IgA disease (LAD) are autoimmune subepidermal blistering skin diseases associated with autoantibodies against the transmembrane hemidesmosomal protein BP180/type XVII collagen. It has been demonstrated previously that BP is characterized predominantly by IgG autoantibodies, while autoantibodies in LAD mainly belong to the IgA isotype. The aim of the present study was to investigate the hypothesis that there is a significant overlap in the autoantibody isotype profiles associated with these two diseases. Several new recombinant forms of BP180 were generated in the baculovirus expression system, including the full-length protein. IgG autoantibodies to BP 180 were detectable in 39 of 40 (98%) of BP sera; interestingly, 88% of BP sera also contained IgA anti-BP180 autoantibodies. Similarly, anti-BP180 reactivity in LAD sera (n=22) was also attributed to both an IgA (68%) and an IgG (76%) autoantibody response. IgA and IgG autoantibodies to the intracellular portion of BP180 were found in 14% and 28% of BP sera, respectively, and in 8% of LAD sera (same percentage for both isotypes). Our findings clearly demonstrate that both BP and LAD patients have a dual IgA and IgG autoimmune response to BP180 which is directed not only to the ectodomain, but also to the intracellular portion of this protein.
authors.affiliation: Institute for Immunology, Pathology and Molecular Biology (IPM), Hamburg, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Kromminga
authors.forename: C
authors.initials: C
authors.lastname: Scheckenbach
authors.forename: M
authors.initials: M
authors.lastname: Georgi
authors.forename: C
authors.initials: C
authors.lastname: Hagel
authors.forename: R
authors.initials: R
authors.lastname: Arndt
authors.forename: E
authors.initials: E
authors.lastname: Christophers
authors.forename: E B
authors.initials: EB
authors.lastname: Bröcker
authors.forename: D
authors.initials: D
authors.lastname: Zillikens
mesh_terms: D000328:Adult; D000368:Aged; D000818:Animals; D001323:Autoantibodies / Q000097:blood / Q000276:immunology*; D001324:Autoantigens / Q000235:genetics / Q000276:immunology*; D001327:Autoimmune Diseases / Q000097:blood / Q000276:immunology*; D001665:Binding Sites; D001768:Blister / Q000097:blood / Q000276:immunology*; D002460:Cell Line; D003001:Cloning, Molecular; D018076:DNA, Complementary; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood / Q000276:immunology*; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D015603:Keratinocytes; D008297:Male; D008875:Middle Aged; D024041:Non-Fibrillar Collagens; D010391:Pemphigoid, Bullous / Q000097:blood / Q000276:immunology*; D011817:Rabbits; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000276:immunology; D018411:Spodoptera / Q000166:cytology; D000097805:Collagen Type XVII
chemical_list: D001323:Autoantibodies; D001324:Autoantigens; D018076:DNA, Complementary; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D024041:Non-Fibrillar Collagens; D011993:Recombinant Fusion Proteins; D000097805:Collagen Type XVII